The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study
Gao et al.,
The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study,
Aging, doi:10.18632/aging.202557
Retrospective 76 COVID-19 patients, 46 treated with intravenous high-dose vitamin C, showing lower mortality and improved oxygen requirements with treatment. Dosage was 6g intravenous infusion per 12hr on the first day, and 6g once for the following 4 days.
risk of death, 86.0% lower, HR 0.14, p = 0.04, treatment 1 of 46 (2.2%), control 5 of 30 (16.7%), NNT 6.9, adjusted per study, KM.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Gao et al., 26 Feb 2021, retrospective, China, peer-reviewed, 14 authors.
Abstract: www.aging-us.com
AGING 2021, Vol. 13, No. 5
Research Paper
The efficiency and safety of high-dose vitamin C in patients with
COVID-19: a retrospective cohort study
Dengfeng Gao1,*, Min Xu1,*, Gang Wang2, Jianrui Lv3, Xiaorong Ma4, Yonghong Guo5, Dexin
Zhang6, Huiyun Yang7, Wei Jiang1, Fuxue Deng1, Guozhi Xia1, Ziwei Lu1, Lv Lv1, Shouping Gong8
1
Department of Cardiology, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
Department of Critical Care, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
3
Department of Anesthesiology, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R.
China
4
Department of Hematology, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
5
Department of Infectious Diseases, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R.
China
6
Department of Respiratory and Critical Care, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an,
Shaanxi, P.R. China
7
Department of Nursing, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
8
Department of Neurosurgery, The Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China
*Equal contribution
2
Correspondence to: Shouping Gong, Dengfeng Gao; email: shpingg@mail.xjtu.edu.cn, gaomedic@mail.xjtu.edu.cn
Keywords: coronavirus disease 2019, COVID-19, ascorbic acid, mortality, safety
Received: October 28, 2020
Accepted: January 4, 2021
Published: February 26, 2021
Copyright: © 2021 Gao et al. This is an open access article distributed under the terms of the Creative Commons Attribution
License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original
author and source are credited.
ABSTRACT
Background: The inflammatory reaction is the main cause of acute respiratory distress syndrome and multiple
organ failure in patients with Coronavirus disease 2019, especially those with severe and critical illness. Several
studies suggested that high-dose vitamin C reduced inflammatory reaction associated with sepsis and acute
respiratory distress syndrome. This study aimed to determine the efficacy and safety of high-dose vitamin C in
Coronavirus disease 2019.
Methods: We included 76 patients with Coronavirus disease 2019, classified into the high-dose vitamin C group
(loading dose of 6g intravenous infusion per 12 hr on the first day, and 6g once for the following 4 days, n=46)
and the standard therapy group (standard therapy alone, n=30).
Results: The risk of 28-day mortality was reduced for the high-dose vitamin C versus the standard therapy
group (HR=0.14, 95% CI, 0.03-0.72). Oxygen support status was improved more with high-dose vitamin C than
standard therapy (63.9% vs 36.1%). No safety events were associated with high-dose vitamin C therapy.
Conclusion: High-dose vitamin C may reduce the mortality and improve oxygen support status in patients with
Coronavirus disease 2019 without adverse events.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit